Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALERE INC.ALR · Entity 172772 | Director | November 15, 2016 | November 17, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALERE INC.
Report date November 15, 2016 · Filed November 17, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,530 |
Reported balance
After 2016-11-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-11-15 · Grant · Acquired 5,530 · Balance 5,530 F3: All prior equity awards granted to the Reporting Person had vested in full on or prior to June 30, 2016. F1: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. F2: The restricted stock units will vest in full on June 30, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Alere common stock.
F2: The restricted stock units will vest in full on June 30, 2017.
F3: All prior equity awards granted to the Reporting Person had vested in full on or prior to June 30, 2016.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Organogenesis Holdings Inc.
Report date December 10, 2018 · Filed December 12, 2018
Section 16 reporting ended · disclosed 2018-12-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 69,571 |
Reported balance
After 2018-12-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-10 · Disposition to issuer · Disposed 243,896 · Balance 69,571 F1: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F2: 243,896 Class B ordinary shares were forfeited to the Issuer for no consideration prior to the closing of the Business Combination. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date.
F2: 243,896 Class B ordinary shares were forfeited to the Issuer for no consideration prior to the closing of the Business Combination.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2018 Filed Dec 12, 2018 21:46 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Disposition to issuerClass B Ordinary Shares · Derivative | 243,896 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-045056 · form4.xml · derivative · entry 1 Bjorklund Hakan · CIK 0001583056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,571 Underlying: Class A Ordinary Shares · 243,896 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F2 · kind: 243,896 Class B ordinary shares were forfeited to the Issuer for no consideration prior to the closing of the Business Combination. F2 · price: 243,896 Class B ordinary shares were forfeited to the Issuer for no consideration prior to the closing of the Business Combination. F1 · derivative.exercise_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 18:21 UTC | Organogenesis Holdings Inc. AHPA · Entity 6275 | OtherClass B Ordinary Shares · Derivative | 7,158 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-065499 · a4.xml · derivative · entry 1 Bjorklund Hakan · CIK 0001583056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,467 Underlying: Class A Ordinary Shares · 7,158 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F2 · kind: 7,158 Class B ordinary shares were transferred to Avista Acquisition Corp. for no consideration. F2 · price: 7,158 Class B ordinary shares were transferred to Avista Acquisition Corp. for no consideration. F1 · derivative.exercise_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. Read SEC document |
| August 17, 2018 Filed Oct 15, 2018 20:46 UTC | Organogenesis Holdings Inc. AHPA · Entity 6275 | Disposition to issuerClass B Ordinary Shares · Derivative | 106,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-062191 · a4.xml · derivative · entry 1 Bjorklund Hakan · CIK 0001583056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,625 Underlying: Class A Ordinary Shares · 106,875 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F2 · kind: 106,875 Class B ordinary shares were forfeited to the Issuer for no consideration. F2 · price: 106,875 Class B ordinary shares were forfeited to the Issuer for no consideration. F1 · derivative.exercise_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. Read SEC document |
| November 25, 2016 Filed Nov 29, 2016 16:42 UTC | Organogenesis Holdings Inc. AHPA · Entity 6275 | Disposition to issuerClass B Ordinary Shares · Derivative | 43,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-16-088071 · form4.xml · derivative · entry 1 Bjorklund Hakan · CIK 0001583056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,500 Underlying: Class A Ordinary Shares · 43,750 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F2 · kind: 43,750 shares of the Class B Shares were forfeited to the Issuer at no cost in connection with the underwriters' election not to exercise the remaining unused portion of the over-allotment option, as described in the Issuer's registration statement on Form S-1 (File No. 333-213465). F2 · price: 43,750 shares of the Class B Shares were forfeited to the Issuer at no cost in connection with the underwriters' election not to exercise the remaining unused portion of the over-allotment option, as described in the Issuer's registration statement on Form S-1 (File No. 333-213465). F1 · derivative.exercise_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 17:51 UTC | ALERE INC. ALR · Entity 172772 | GrantRestricted Stock Units · Derivative | 5,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-031796 · edgar.xml · derivative · entry 1 Bjorklund Hakan · CIK 0001583056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,530 Underlying: Common Stock · 5,530 shares Expires not disclosed F3 · security: All prior equity awards granted to the Reporting Person had vested in full on or prior to June 30, 2016. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. F2 · derivative.exercise_date: The restricted stock units will vest in full on June 30, 2017. F2 · derivative.expiration_date: The restricted stock units will vest in full on June 30, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.